 Anavex Life Sciences Corp NASDAQ: AVXL has reported new preclinical data for its Alzheimers candidate, ANAVEX2-73 blarcamesine. Pre-treatment with blarcamesine repeated once daily for one week before the Aβ Abeta challenge was protective in the Aβ25-35 peptide model of Alzheimers mice model. 